Stockscreener 앱 받기
17.00
0.18%
0.03
Crescent Biopharma Inc 주식(CBIO)의 최신 뉴스
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Balyasny Asset Management L.P. Expands Stake in Crescent Biophar - GuruFocus
Crescent Biopharma (NASDAQ:CBIO) Stock Price Up 4.9%Should You Buy? - MarketBeat
Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Gap DownShould You Sell? - MarketBeat
Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support LevelDay Trade Opportunities - vinanet.vn
Crescent Biopharma Ord Shs (CBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CBIO Q2 2026 Earnings: Narrower-Than-Expected Loss Buoys SharesRevenue Miss Report - vinanet.vn
Q3 EPS Forecast for Crescent Biopharma Lowered by Analyst - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
CRESCENT BIOPHARMA, INC. SEC Filing (Aug 3, 2026) - Stock Titan
Perceptive Advisors LLC Lowers Stake in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (CBIO) Gets a Buy from Wedbush - The Globe and Mail
Crescent Biopharma Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Crescent Biopharma Reports Q2 2026 Results and Advances Clinical Development of CR-001, CR-002 and CR-003 - Quiver Quantitative
Crescent Biopharma: Q2 Earnings Snapshot - KING5.com
Crescent Biopharma posts $24.8 million Q2 net loss - Quiver Quantitative
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma Q2 Results: EPS beats estimates, losses narrow - scanx.trade
Exome Asset Management LLC Makes New $2.81 Million Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Crescent Biopharma Market Sentiment - Benzinga España
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crescent Biopharma Ord Shs (CBIO) Institutional Confidence - TradingKey
Crescent Biopharma (CBIO) Faces Selling Pressure, Testing Key Support After 4.29% DeclineTechnical Analysis - dars.gov.et
CBIO|Crescent Biopharma Ord Shs|Price:16.300|Chg%:-0.730 - TradingKey
Crescent Biopharma (CBIO) Shares Dip 4.3% as Stock Pulls Back Toward Key SupportDefined Outcome ETF - dars.gov.et
Crescent Biopharma grants inducement stock options for 52,500 shares at $15.83 each - Bitget
Two Crescent Biopharma Employees Receive 52,500 Stock Options - Stock Titan
CBIO Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers Positive Surprise as Pipeline Progress ContinuesRevenue Inflection Point - vinanet.vn
CBIO Options Volatility — NASDAQ:CBIO - TradingView
Jennison Associates LLC Invests $2.81 Million in Crescent Biopharma, Inc. $CBIO - MarketBeat
Fairmount Healthcare Fund II LP acquires 853,450 Crescent Biopharma shares for $12.38 million - Bitget
Fairmount Funds' $12 Million Bet on Crescent Biopharma: A Strong Signal Amidst Volatility - Kavout | AI
Insider fund at Crescent Biopharma (NASDAQ: CBIO) buys 1.38M shares, warrants - Stock Titan
Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal - Stock Titan
CBIO Q1 2026 Earnings: Better-than-Expected Loss as Biotech Continues DevelopmentInvestor Earnings Call - vinanet.vn
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma (CBIO) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Crescent Biopharma closes $143.7 million public offering - Investing.com
Crescent Biopharma closes $143.7 million public offering By Investing.com - Investing.com Nigeria
Crescent Biopharma (CBIO) Proxy filing Summary - Quartr
Press Release: Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Moomoo
Crescent Biopharma (CBIO) Bank of America Global Healthcare Conference 2026 Summary - Quartr
H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Hold Rating - Moomoo
Form 424B5 Crescent Biopharma Inc For: 15 July By Investing.com - Investing.com Canada
Crescent Bi raises up to $133.5M in registered offering of 8.09M shares and pre-funded warrants - TradingView
Crescent Biopharma (Nasdaq: CBIO) prices $125.0 million stock and warrant sale - Stock Titan
Form 424B5 CRESCENT BIOPHARMA, INC. - StreetInsider
Crescent Biopharma (Nasdaq: CBIO) targets approximately $115.9 million raise - Stock Titan
Crescent Biopharma Prices $125 Million Common, Warrant Offering - marketscreener.com
Crescent Biopharma, Inc. Files 8-K with SEC – Ordinary Shares (CBIO) Listed on NASDAQ, Key Company Details for July 2026 141649 – Minichart - Minichart
Form 424B5 Crescent Biopharma Inc For: 14 July - Investing.com UK
Crescent Biopharma prices $125M public offering at $14.50/share By Investing.com - Investing.com Nigeria
Crescent Biopharma launches public offering of ordinary shares By Investing.com - Investing.com Nigeria
Crescent Biopharma prices $125M public offering at $14.50/share - Investing.com
Crescent Biopharma Underwriters Have Option for Nearly 1.3M Additional Shares >CBIO - Moomoo
Crescent Biopharma prices $125M public offering of shares and pre-funded warrants - Pluang
Crescent Biopharma Expects Offering to Close July 16 >CBIO - Moomoo
Crescent Biopharma Also Offering Certain Investors Prefunded Warrants to Buy 525,897 Shares >CBIO - Moomoo
0.07%
1.21%
자본화:
|
볼륨(24시간):